These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23968672)

  • 1. Cost-control mechanisms in Canadian private drug plans.
    Kratzer J; McGrail K; Strumpf E; Law MR
    Healthc Policy; 2013 Aug; 9(1):35-43. PubMed ID: 23968672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.
    Régnier SA
    Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated cost of universal public coverage of prescription drugs in Canada.
    Morgan SG; Law M; Daw JR; Abraham L; Martin D
    CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Private expenditures on brand name prescription drugs after generic entry.
    Balaban DY; Dhalla IA; Law MR; Bell CM
    Appl Health Econ Health Policy; 2013 Oct; 11(5):523-9. PubMed ID: 23979876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing employer-sponsored and federal exchange plans: wide variations in cost sharing for prescription drugs.
    Buttorff C; Andersen MS; Riggs KR; Alexander GC
    Health Aff (Millwood); 2015 Mar; 34(3):467-76. PubMed ID: 25732498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
    Kennedy J; Morgan S
    Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does complementary private prescription drug insurance coverage affect seniors' use of publicly funded medications?
    Allin S; Law MR; Laporte A
    Health Policy; 2013 May; 110(2-3):147-55. PubMed ID: 23522381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs.
    Charbonneau M; Gagnon MA
    Health Policy; 2018 Dec; 122(12):1295-1301. PubMed ID: 30241797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Employers push to manage prescription drug costs.
    Frieden J
    Bus Health; 1992 May; 10(6):43-6, 48, 50. PubMed ID: 10119119
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacy benefits: new concepts in plan design.
    Goff VV
    NHPF Issue Brief; 2002 Mar; (772):1-16. PubMed ID: 11915906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug benefits: Rx for cost management--commentary.
    Carlsen MA
    Benefits Q; 1993; 9(3):81-8. PubMed ID: 10127207
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
    Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
    J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of copayments and generic substitution on the use and costs of prescription drugs.
    Smith DG
    Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
    Murry L; Gerleman B; Urick B; Urmie J
    J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.